CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.31B, above the global median of $1.15B
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
0.65%
Annual Rate
CNY 0.40Paid semi-annual
Payout Ratio
138.7%High
Last Ex-Dividend
Jul 10, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
8.80BCNY1.31B · vs all stocks (USD)
Trailing P/E
201.81xvs Biotechnology peers
Revenue (TTM)
453.39MCNY67.42M · vs all stocks (USD)
Profit Margin
14.61%vs Biotechnology peers
Beta
0.6550xvs all stocks
52-Week Change
11.20%vs all stocks
Forward Annual Dividend Yield
0.65%vs all stocks
Market Capitalization
8.80BCNY1.31B · vs all stocks (USD)
Enterprise Value
7.25BCNY1.08B · vs all stocks (USD)
Trailing P/E
201.81xvs Biotechnology peers
Forward P/E
71.11xvs Biotechnology peers
Price to Sales (TTM)
19.62xvs Biotechnology peers
Price to Book (MRQ)
2.97xvs Biotechnology peers
Enterprise to Revenue
15.99xvs Biotechnology peers
Enterprise to EBITDA
128.31xvs Biotechnology peers
Gross Margin
43.79%vs Biotechnology peers
Profit Margin
14.61%vs Biotechnology peers
Operating Margin
4.37%vs Biotechnology peers
Return on Assets (TTM)
0.29%vs Biotechnology peers
Return on Equity (TTM)
2.64%vs Biotechnology peers
Revenue (TTM)
453.39MCNY67.42M · vs all stocks (USD)
Revenue per Share (TTM)
3.87CNYUpdated Aug 21, 2026Quarterly Revenue Growth
117.70%vs Biotechnology peers
Gross Profit (TTM)
202.20MCNY30.07M · vs all stocks (USD)
EBITDA (TTM)
126.49MCNY18.81M · vs all stocks (USD)
Net Income (TTM)
66.26MCNY9.85M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
167.40%vs Biotechnology peers
Operating Cash Flow (TTM)
55.41MCNY8.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
822.28MCNY122.28M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4000CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.65%vs all stocks
Trailing Annual Dividend Rate
0.4300CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.70%vs all stocks
Payout Ratio
138.71%vs Biotechnology peers
Minority Interest (Equity)
-2.15MCNYFY2025 · Dec 31, 2025Revenue
354.91MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
174.44MCNYFY2025 · Dec 31, 2025Gross Profit
180.47MCNYFY2025 · Dec 31, 2025Operating Income
37.81MCNY5.62M · vs all stocks (USD)
Pre-tax Income
49.37MCNYFY2025 · Dec 31, 2025Income Tax Expense
8.36MCNYFY2025 · Dec 31, 2025Net Income
41.02MCNYFY2025 · Dec 31, 2025EBIT
52.07MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
126.49MCNYFY2025 · Dec 31, 2025Research & Development
48.38MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.72MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.08MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
16.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
112.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
112.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
41.02MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
680.06KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
46.20MCNYFY2025 · Dec 31, 2025Free Cash Flow
-9.87MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
767.10MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
41.02MCNYFY2025 · Dec 31, 2025Other Non-cash Items
18.79MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.20MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.81MCNYFY2025 · Dec 31, 2025Capital Expenditures
-56.07MCNYFY2025 · Dec 31, 2025Purchase of Investments
-45.00MCNYFY2025 · Dec 31, 2025Other Investing Activity
-56.58MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-157.64MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
115.00KCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-115.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-48.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
-8.23MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-57.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
139.27MSharesUpdated Aug 21, 2026Float Shares
93.74MSharesUpdated Aug 21, 2026% Held by Insiders
31.90%vs all stocks
% Held by Institutions
29.06%vs all stocks
Total Cash (MRQ)
1.82BCNY271.15M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.09CNYUpdated Aug 21, 2026Total Debt (MRQ)
169.78MCNY25.25M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0619xvs Biotechnology peers
Current Ratio (MRQ)
1.90xvs Biotechnology peers
Book Value per Share (MRQ)
21.08CNYUpdated Aug 21, 2026Total Assets
2.25BCNY334.09M · vs all stocks (USD)
Total Current Assets
1.56BCNYFY2025 · Dec 31, 2025Total Liabilities
148.29MCNYFY2025 · Dec 31, 2025Total Non-current Assets
682.03MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
71.44MCNYFY2025 · Dec 31, 2025Total Current Liabilities
76.86MCNYFY2025 · Dec 31, 2025Cash
767.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.43MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
787.45MCNYFY2025 · Dec 31, 2025Other Short-term Investments
246.73MCNYFY2025 · Dec 31, 2025Accounts Receivable
94.85MCNYFY2025 · Dec 31, 2025Inventory
73.79MCNYFY2025 · Dec 31, 2025Accounts Payable
24.09MCNYFY2025 · Dec 31, 2025Short-term Debt
14.92MCNYFY2025 · Dec 31, 2025Other Current Liabilities
493.76KCNYFY2025 · Dec 31, 2025Long-term Debt
42.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
113.82MCNYFY2025 · Dec 31, 2025Retained Earnings
77.30MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.10BCNY312.04M · vs all stocks (USD)
52-Week Low
34.13CNYUpdated Aug 21, 202652-Week High
71.88CNYUpdated Aug 21, 202652-Week Change
11.20%vs all stocks
Beta
0.6550xvs all stocks
50-Day MA
50.09CNYUpdated Aug 21, 2026200-Day MA
50.28CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.03MSharesUpdated Aug 21, 2026Avg 30-Day Volume
5.28MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.3100CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 1.18Receivables vs revenue divergence: 7.24
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.39Dividend per Share: 0.43Earnings per Share: 0.31
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.31B, above the global median of $1.15BNotable
Market cap (USD): 1,308,284,417.731Global Median: 1,146,734,693.424
Levered free cash flow is $122.28M, above the global median of $16.24MNotable
Levered free cash flow (USD): 122,281,401.562Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
LB Pharmaceuticals Inc.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Pulse Biosciences Inc.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
PensionBee Group plc
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity